On July 1998, IMPATH Inc. (NASDAQ: IMPH) acquired BIS Laboratories. BIS is a leader in the field of lymph node and bone marrow micrometastases analyses focusing exclusively on the ultra-sensitive detection of early dissemination of disease, post-chemotherapy characterization of minimal residual disease and assessment of bone marrow harvested for transplantation.